Total Voting Rights

Skyepharma PLC (the "Company")

Total Voting Rights

In compliance with the Financial Conduct Authority's Disclosure and Transparency Rules, we hereby notify the market of the following:

On 31 March 2016, the Company had 105,912,259 issued Ordinary shares of £1.00 each with voting rights and admitted to trading. This is an increase of 1,100,000 ordinary shares since the previous total voting rights announcement made by the Company on 29 April 2014 within the announcement "Completion of Capital Raising and Admission of New Shares" .

The Company does not hold any ordinary shares in treasury and has no other category of share admitted to trading or holding voting rights.

These total voting rights figures may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com